Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A, C, Y, W135 meningococcal polysaccharide vaccine
- Development stage
- Unknown
- Lead developer
- EpiCentre
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular
01
Overview
The A, C, Y, W135 meningococcal polysaccharide vaccine is a tetravalent biologic designed to prevent invasive disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W135. It consists of purified capsular polysaccharides from each of the four target serogroups. The vaccine functions by inducing the production of serogroup-specific bactericidal antibodies, which provide immunity against the bacteria. This specific entry refers to research conducted by Epicentre (the research arm of Médecins Sans Frontières) in Uganda, which evaluated the immunogenicity of fractional doses (1/5 and 1/10 of the standard dose) to extend vaccine supplies during outbreaks in the African Meningitis Belt. The standard full dose typically contains 50 μg of each polysaccharide component.
- Other names
- Tetravalent meningococcal polysaccharide vaccineFractional dose ACWY polysaccharide vaccineA, C, Y, W135 meningococcal polysaccharide vaccine-Epicentre-Meningococcal meningitis
02
Targets
BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on A, C, Y, W135 meningococcal polysaccharide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on A, C, Y, W135 meningococcal polysaccharide vaccine.